GlassScriptPhysician profile
Mark Ronald Pomaranski
NPI 1962511097
$1,721.27
in general payments reported to CMS, 2019-2025
16 companies · $372 in 2025
The $372 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $200 · 2020: $162 · 2021: $238 · 2022: $122 · 2023: $280 · 2024: $347 · 2025: $372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $999.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $998.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $481.06 | 2019-2025 | |
| Abbvie INC. | $360.27 | 2019-2025 | |
| Genzyme Corporation | $129.51 | 2021-2025 | |
| Janssen Biotech, INC. | $125.41 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Lilly USA, LLC | $108.55 | 2021-2024 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $107.62 | 2021-2025 | Ilumya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.95 | 2023-2025 | Spevigo |
| Regeneron Healthcare Solutions, INC. | $78.85 | 2019-2024 | Dupixent |
| Prugen, INC. Pharmaceuticals | $64.37 | 2019-2020 | |
| Incyte Corporation | $42.16 | 2022-2023 | Opzelura |
| Dermira, INC. | $37.43 | 2019-2020 | |
| Smith+Nephew, INC. | $24.64 | 2019 | |
| Kyowa Kirin, INC. | $23.36 | 2019 | |
| Medtronic, INC. | $18.81 | 2022 | |
| Ucb, INC. | $18.18 | 2025 | Bimzelx |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $13.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Pomaranski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.